{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T02:41:31Z","timestamp":1788489691445,"version":"build-2803163510"},"reference-count":83,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100012802","name":"Ragon Institute of MGH, MIT and Harvard","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R37 AI170189"],"award-info":[{"award-number":["R37 AI170189"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.ymthe.2024.06.022","type":"journal-article","created":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T10:38:10Z","timestamp":1725187090000},"page":"3485-3503","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5246-4187","authenticated-orcid":false,"given":"Colby R.","family":"Maldini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica C.","family":"Messana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula B.","family":"Bendet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Camblin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faith M.","family":"Musenge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moriah L.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph J.","family":"Rocha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey J.","family":"Coholan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cisem","family":"Karaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir D.","family":"Vrbanac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Marte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel T.","family":"Claiborne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian L.","family":"Boutwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd M.","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.06.022_bib1","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.omtm.2021.06.014","article-title":"Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T\u00a0cells during large-scale cGMP manufacturing","volume":"22","author":"Wang","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.06.022_bib2","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1111\/trf.14003","article-title":"Autologous lymphapheresis for the production of chimeric antigen receptor T\u00a0cells","volume":"57","author":"Allen","year":"2017","journal-title":"Transfusion (Paris)"},{"key":"10.1016\/j.ymthe.2024.06.022_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u2019 allogeneic CAR T\u00a0cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.06.022_bib4","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1182\/blood.V68.3.770.770","article-title":"Clonable T lymphocytes in T\u00a0cell-depleted bone marrow transplants correlate with development of graft-v-host disease","volume":"68","author":"Kernan","year":"1986","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.022_bib5","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T\u00a0cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.06.022_bib6","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.1158\/0008-5472.CAN-14-3321","article-title":"Multiplex genome-edited T-cell manufacturing platform for \u201coff-the-shelf\u201d adoptive T-cell immunotherapies","volume":"75","author":"Philip","year":"2015","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.06.022_bib7","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1056\/NEJM198901263200401","article-title":"Effect of HLA Compatibility on Engraftment of Bone Marrow Transplants in Patients with Leukemia or Lymphoma","volume":"320","author":"Anasetti","year":"1989","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.022_bib8","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1158\/2326-6066.CIR-18-0508","article-title":"Genetic ablation of HLA class I, class II, and the T-cell receptor enables allogeneic T\u00a0cells to be used for adoptive T-cell therapy","volume":"8","author":"Kagoya","year":"2020","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.06.022_bib9","article-title":"Abrogation of HLA surface expression using CRISPR\/Cas9 genome editing: a step toward universal T\u00a0cell therapy","volume":"10","author":"Lee","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.06.022_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1038\/319675a0","article-title":"Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy","volume":"319","author":"K\u00e4rre","year":"1986","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.06.022_bib11","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.drudis.2015.05.006","article-title":"Sirolimus and everolimus in kidney transplantation","volume":"20","author":"Moes","year":"2015","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ymthe.2024.06.022_bib12","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.healun.2004.02.022","article-title":"Overview of tacrolimus-based immunosuppression after heart or lung transplantation","volume":"24","author":"Reichenspurner","year":"2005","journal-title":"J.\u00a0Heart Lung Transpl."},{"key":"10.1016\/j.ymthe.2024.06.022_bib13","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040613","article-title":"Effect of early post-transplantation tacrolimus concentration on the risk of acute graft-versus-host disease in allogenic stem\u00a0cell transplantation","volume":"13","author":"Sharma","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.06.022_bib14","article-title":"The Addition of Sirolimus to GVHD Prophylaxis After Allogeneic Hematopoietic Stem Cell Transplantation: A Meta-Analysis of Efficacy and Safety","volume":"11","author":"Chen","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib15","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1126\/science.1702904","article-title":"Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands","volume":"251","author":"Schreiber","year":"1991","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.06.022_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1006\/bbrc.1994.2140","article-title":"A putative sirolimus (rapamycin) effector protein","volume":"203","author":"Chen","year":"1994","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ymthe.2024.06.022_bib17","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1038\/369756a0","article-title":"A mammalian protein targeted by G1-arresting rapamycin-receptor complex","volume":"369","author":"Brown","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.06.022_bib18","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1074\/jbc.270.2.815","article-title":"Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells","volume":"270","author":"Sabers","year":"1995","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ymthe.2024.06.022_bib19","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1002\/j.1460-2075.1990.tb07893.x","article-title":"The actions of cyclosporin A and FK506 suggest a novel step in the activation of T lymphocytes","volume":"9","author":"Mattila","year":"1990","journal-title":"EMBO J."},{"key":"10.1016\/j.ymthe.2024.06.022_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/jcp.1041540103","article-title":"Rapamycin blocks cell cycle progression of activated T\u00a0cells prior to events characteristic of the middle to late G1 phase of the cycle","volume":"154","author":"Terada","year":"1993","journal-title":"J.\u00a0Cell. Physiol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.4049\/jimmunol.144.1.251","article-title":"Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin","volume":"144","author":"Dumont","year":"1990","journal-title":"J. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib22","doi-asserted-by":"crossref","first-page":"718","DOI":"10.4049\/jimmunol.143.2.718","article-title":"The immunosuppressant FK506 selectively inhibits expression of early T\u00a0cell activation genes","volume":"143","author":"Tocci","year":"1989","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib23","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.7164\/antibiotics.40.1256","article-title":"Fk-506, A Novel Immunosuppressant Isolated From A Streptomyces Ii. Immunosuppressive Effect Of Fk-506 In\u00a0Vitro","volume":"40","author":"Kino","year":"1987","journal-title":"J.\u00a0Antibiot."},{"key":"10.1016\/j.ymthe.2024.06.022_bib24","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.stem.2013.11.014","article-title":"An effective approach to prevent immune rejection of human ESC-derived allografts","volume":"14","author":"Rong","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.06.022_bib25","article-title":"Ex\u00a0vivo expanded human regulatory T\u00a0cells delay islet\u00a0allograft rejection via inhibiting islet-derived monocyte chemoattractant protein-1 production in CD34+ stem cells-reconstituted NOD-scid IL2r\u03b3null mice","volume":"9","author":"Xiao","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.06.022_bib26","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1084\/jem.20082013","article-title":"IL-15 trans-presentation promotes human NK cell development and differentiation in\u00a0vivo","volume":"206","author":"Huntington","year":"2009","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2024.06.022_bib27","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010112","article-title":"Differences in Tumor Growth and Differentiation in NSG and Humanized-BLT Mice; Analysis of Human vs. Humanized-BLT-Derived NK Expansion and Functions","volume":"15","author":"Kaur","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.06.022_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1182\/blood-2002-07-2024","article-title":"Human NK cell development in NOD\/SCID mice receiving grafts of cord blood CD34+ cells","volume":"102","author":"Kalberer","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.022_bib29","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17442-7","article-title":"Long-term maintenance of peripheral blood derived human NK cells in a novel human IL-15- transgenic NOG mouse","volume":"7","author":"Katano","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.06.022_bib30","doi-asserted-by":"crossref","first-page":"2513","DOI":"10.1002\/eji.202049107","article-title":"Mutant B2M-HLA-E and B2M-HLA-G fusion proteins protects universal chimeric antigen receptor-modified T\u00a0cells from allogeneic NK cell-mediated lysis","volume":"51","author":"Guo","year":"2021","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib31","article-title":"Simultaneous editing of TCR, HLA-I\/II and HLA-E resulted in enhanced universal CAR-T resistance to allo-rejection","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-022-30896-2","article-title":"Endowing universal CAR T-cell with immune-evasive properties using TALEN-gene editing","volume":"13","author":"Jo","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.022_bib33","doi-asserted-by":"crossref","DOI":"10.1038\/srep21757","article-title":"Genetic editing of HLA expression in hematopoietic stem cells to broaden their human application","volume":"6","author":"Torikai","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ymthe.2024.06.022_bib34","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.stem.2019.02.005","article-title":"Targeted Disruption of HLA Genes via CRISPR-Cas9 Generates iPSCs with Enhanced Immune Compatibility","volume":"24","author":"Xu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.06.022_bib35","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.4161\/cbt.8.23.10455","article-title":"Natural killer cells and cancer: Regulation by the killer cell ig-like receptors (KIR)","volume":"8","author":"Purdy","year":"2009","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.022_bib36","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.stemcr.2017.07.020","article-title":"NK Cell Alloreactivity against KIR-Ligand-Mismatched HLA-Haploidentical Tissue Derived from HLA Haplotype-Homozygous iPSCs","volume":"9","author":"Ichise","year":"2017","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.ymthe.2024.06.022_bib37","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.022_bib38","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-020-0280-y","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"10","author":"Liu","year":"2020","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2024.06.022_bib39","doi-asserted-by":"crossref","DOI":"10.3390\/biom13020382","article-title":"Early Use of Corticosteroids following CAR T-Cell Therapy Correlates with Reduced Risk of High-Grade CRS without Negative Impact on Neurotoxicity or Treatment Outcome","volume":"13","author":"Lakomy","year":"2023","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymthe.2024.06.022_bib40","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/modpathol.2012.141","article-title":"Activity and complexes of mTOR in diffuse large B-cell lymphomas - A tissue microarray study","volume":"25","author":"Sebesty\u00e9n","year":"2012","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib41","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.leukres.2012.07.016","article-title":"Activation of mammalian target of rapamycin in diffuse large B-cell lymphoma: A clinicopathological study","volume":"36","author":"Vajpayee","year":"2012","journal-title":"Leuk. Res."},{"key":"10.1016\/j.ymthe.2024.06.022_bib42","doi-asserted-by":"crossref","first-page":"7350","DOI":"10.1073\/pnas.91.15.7350","article-title":"Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2","volume":"91","author":"Gottschalk","year":"1994","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.06.022_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00007890-199508000-00010","article-title":"Rapamycin, a potent immunosuppressive drug, causes programmed cell death in B lymphoma cells","volume":"60","author":"Muthukkumar","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2024.06.022_bib44","article-title":"Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells","author":"Hammer","year":"2023","journal-title":"bioRxiv."},{"key":"10.1016\/j.ymthe.2024.06.022_bib45","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41551-021-00730-z","article-title":"Generation of hypoimmunogenic T\u00a0cells from genetically engineered allogeneic human induced pluripotent stem cells","volume":"5","author":"Wang","year":"2021","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2024.06.022_bib46","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.1073\/pnas.1902566116","article-title":"Generation of hypoimmunogenic human pluripotent stem cells","volume":"116","author":"Han","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.06.022_bib47","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41467-023-37785-2","article-title":"Hypoimmune anti-CD19 chimeric antigen receptor T\u00a0cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice","volume":"14","author":"Hu","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.022_bib48","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/nbt.4192","article-title":"Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements","volume":"36","author":"Kosicki","year":"2018","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib49","doi-asserted-by":"crossref","first-page":"E8","DOI":"10.1038\/s41586-018-0380-z","article-title":"Large deletions induced by Cas9 cleavage","volume":"560","author":"Adikusuma","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.06.022_bib50","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41588-021-00838-7","article-title":"Chromothripsis as an on-target consequence of CRISPR-Cas9 genome editing","volume":"53","author":"Leibowitz","year":"2021","journal-title":"Nat. Genet."},{"key":"10.1016\/j.ymthe.2024.06.022_bib51","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.omtm.2021.04.007","article-title":"The impact of lentiviral vector genome size and producer cell genomic to gag-pol mRNA ratios on packaging efficiency and titre","volume":"21","author":"Sweeney","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.06.022_bib52","doi-asserted-by":"crossref","first-page":"9933","DOI":"10.1128\/JVI.79.15.9933-9944.2005","article-title":"Packaging capacity of adeno-associated virus serotypes: impact of larger genomes on infectivity and postentry steps","volume":"79","author":"Grieger","year":"2005","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib53","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","article-title":"Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma","volume":"27","author":"Hess","year":"2009","journal-title":"J.\u00a0Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib54","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/leu.2010.226","article-title":"A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma","volume":"25","author":"Witzig","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.ymthe.2024.06.022_bib55","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T\u00a0cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib56","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/ejh.14052","article-title":"Hematopoiesis and immune reconstitution after CD19 directed chimeric antigen receptor T-cells (CAR-T): A comprehensive review on incidence, risk factors and current management","volume":"112","author":"Galli","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib57","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.06.022_bib58","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.022_bib59","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","article-title":"Anti-CD19 CAR T\u00a0cell therapy for refractory systemic lupus erythematosus","volume":"28","author":"Mackensen","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.06.022_bib60","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071684","article-title":"Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed\/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma","volume":"13","author":"Korell","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.06.022_bib61","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.celrep.2018.04.051","article-title":"Engineered Tumor-Targeted T Cells Mediate Enhanced Anti-Tumor Efficacy Both Directly and through Activation of the Endogenous Immune System","volume":"23","author":"Avanzi","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.ymthe.2024.06.022_bib62","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","article-title":"IFN\u03b3 Is Critical for CAR T Cell-Mediated Myeloid Activation and Induction of Endogenous Immunity","volume":"11","author":"Alizadeh","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ymthe.2024.06.022_bib63","article-title":"Tacrolimus Maintains the Balance of Neutrophil Extracellular Traps by Inducing DNA Methylation of Neutrophils to Reduce Immune Rejection","volume":"13","author":"Xu","year":"2023","journal-title":"Life (Basel)"},{"key":"10.1016\/j.ymthe.2024.06.022_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170806","article-title":"The Effect of Tacrolimus and Mycophenolic Acid on CD14+ Monocyte Activation and Function","volume":"12","author":"Kannegieter","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ymthe.2024.06.022_bib65","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.109424","article-title":"Tacrolimus ameliorates bleomycin-induced pulmonary fibrosis by inhibiting M2 macrophage polarization via JAK2\/STAT3 signaling","volume":"113","author":"Liu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib66","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1097\/TP.0000000000000717","article-title":"Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells","volume":"99","author":"Gallon","year":"2015","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2024.06.022_bib67","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1097\/TP.0b013e3182590d8f","article-title":"In\u00a0vitro effects of cyclosporine A and tacrolimus on regulatory T-cell proliferation and function","volume":"94","author":"Miroux","year":"2012","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2024.06.022_bib68","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1097\/TP.0000000000001379","article-title":"Impact of Immune-Modulatory Drugs on Regulatory T Cell","volume":"100","author":"Furukawa","year":"2016","journal-title":"Transplantation"},{"key":"10.1016\/j.ymthe.2024.06.022_bib69","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.06.022_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2021.636037","article-title":"Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives","volume":"9","author":"Faes","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib71","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1093\/neuonc\/noac024","article-title":"Off-the-shelf, steroid-resistant, IL13R\u03b12-specific CAR T\u00a0cells for treatment of glioblastoma","volume":"24","author":"Brown","year":"2022","journal-title":"Neuro. Oncol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib72","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ymthe.2020.09.011","article-title":"CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients","volume":"29","author":"Amini","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.06.022_bib73","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.1038\/s41467-023-44176-0","article-title":"Cyclosporine A-resistant CAR-T cells mediate antitumour immunity in the presence of allogeneic cells","volume":"14","author":"Zhang","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.06.022_bib74","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1038\/gt.2012.97","article-title":"Efficient selection of genetically modified human T\u00a0cells using methotrexate-resistant human dihydrofolate reductase","volume":"20","author":"Jonnalagadda","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2024.06.022_bib75","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","article-title":"Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T\u00a0cells","volume":"558","author":"Fraietta","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.06.022_bib76","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","article-title":"Clonal expansion of CAR T\u00a0cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy","volume":"3","author":"Shah","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.06.022_bib77","doi-asserted-by":"crossref","first-page":"7305","DOI":"10.1128\/JVI.02207-08","article-title":"Induction of robust cellular and humoral virus-specific adaptive immune responses in human immunodeficiency virus-infected humanized BLT mice","volume":"83","author":"Brainard","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib78","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006613","article-title":"Supraphysiologic control over HIV-1 replication mediated by CD8 T\u00a0cells expressing a re-engineered CD4-based chimeric antigen receptor","volume":"13","author":"Leibman","year":"2017","journal-title":"Plos Pathog."},{"key":"10.1016\/j.ymthe.2024.06.022_bib79","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1038\/s41591-020-1039-5","article-title":"Dual CD4-based CAR T\u00a0cells with distinct costimulatory domains mitigate HIV pathogenesis in\u00a0vivo","volume":"26","author":"Maldini","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.06.022_bib80","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-5890(97)00144-2","article-title":"Construction and characterisation of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukaemia and lymphoma","volume":"34","author":"Nicholson","year":"1997","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib81","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1182\/blood.2022015825","article-title":"Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL","volume":"140","author":"Diorio","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.06.022_bib82","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1038\/s41587-020-0491-6","article-title":"Directed evolution of adenine base editors with increased activity and therapeutic application","volume":"38","author":"Gaudelli","year":"2020","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.06.022_bib83","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jim.2003.10.017","article-title":"The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in\u00a0vitro and in\u00a0vivo","volume":"285","author":"Hermans","year":"2004","journal-title":"J.\u00a0Immunol. Methods"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624004040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T12:49:41Z","timestamp":1758199781000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624004040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":83,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["S1525001624004040"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.022","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppressant therapy averts rejection of allogeneic FKBP1A-disrupted CAR-T cells","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}